Sorting through new biomarkers

Frances O. Wood, James A de Lemos

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Early diagnosis of acute coronary syndromes (ACS) allows for efficient risk stratification, appropriate targeted therapies, and faster patient disposition within crowded emergency departments. Although only troponin testing is recommended for routine use in the 2007 American College of Cardiology/American Heart Association guidelines for non-ST-elevation ACS, emerging data support selected use of other biomarkers, including B-type natriuretic peptides (BNPs) and C-reactive protein. There remains a need to identify additional biomarkers in ACS to enhance risk stratification and to help guide therapeutic decisions in this increasingly complex area of cardiovascular medicine. Cardiac biomarkers may help to diagnosis ACS before cardiomyocyte necrosis, to influence the decision for early invasive treatment, and to provide a means of monitoring response to therapy. In this review, we assess new data in ACS with respect to troponins, BNPs, myeloperoxidase, fatty acid-binding protein, and monocyte chemoattractant protein-1. We also discuss novel biomarkers including growth deficient factor-15 and neopterin.

Original languageEnglish (US)
Pages (from-to)319-326
Number of pages8
JournalCurrent Cardiology Reports
Volume10
Issue number4
DOIs
StatePublished - 2008

Fingerprint

Acute Coronary Syndrome
Biomarkers
Troponin
Brain Natriuretic Peptide
Neopterin
Fatty Acid-Binding Proteins
Chemokine CCL2
Therapeutics
Cardiac Myocytes
C-Reactive Protein
Peroxidase
Hospital Emergency Service
Early Diagnosis
Intercellular Signaling Peptides and Proteins
Necrosis
Medicine
Guidelines

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sorting through new biomarkers. / Wood, Frances O.; de Lemos, James A.

In: Current Cardiology Reports, Vol. 10, No. 4, 2008, p. 319-326.

Research output: Contribution to journalArticle

Wood, Frances O. ; de Lemos, James A. / Sorting through new biomarkers. In: Current Cardiology Reports. 2008 ; Vol. 10, No. 4. pp. 319-326.
@article{4069d96dbb9a4114892197a930cd3bb2,
title = "Sorting through new biomarkers",
abstract = "Early diagnosis of acute coronary syndromes (ACS) allows for efficient risk stratification, appropriate targeted therapies, and faster patient disposition within crowded emergency departments. Although only troponin testing is recommended for routine use in the 2007 American College of Cardiology/American Heart Association guidelines for non-ST-elevation ACS, emerging data support selected use of other biomarkers, including B-type natriuretic peptides (BNPs) and C-reactive protein. There remains a need to identify additional biomarkers in ACS to enhance risk stratification and to help guide therapeutic decisions in this increasingly complex area of cardiovascular medicine. Cardiac biomarkers may help to diagnosis ACS before cardiomyocyte necrosis, to influence the decision for early invasive treatment, and to provide a means of monitoring response to therapy. In this review, we assess new data in ACS with respect to troponins, BNPs, myeloperoxidase, fatty acid-binding protein, and monocyte chemoattractant protein-1. We also discuss novel biomarkers including growth deficient factor-15 and neopterin.",
author = "Wood, {Frances O.} and {de Lemos}, {James A}",
year = "2008",
doi = "10.1007/s11886-008-0051-z",
language = "English (US)",
volume = "10",
pages = "319--326",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Sorting through new biomarkers

AU - Wood, Frances O.

AU - de Lemos, James A

PY - 2008

Y1 - 2008

N2 - Early diagnosis of acute coronary syndromes (ACS) allows for efficient risk stratification, appropriate targeted therapies, and faster patient disposition within crowded emergency departments. Although only troponin testing is recommended for routine use in the 2007 American College of Cardiology/American Heart Association guidelines for non-ST-elevation ACS, emerging data support selected use of other biomarkers, including B-type natriuretic peptides (BNPs) and C-reactive protein. There remains a need to identify additional biomarkers in ACS to enhance risk stratification and to help guide therapeutic decisions in this increasingly complex area of cardiovascular medicine. Cardiac biomarkers may help to diagnosis ACS before cardiomyocyte necrosis, to influence the decision for early invasive treatment, and to provide a means of monitoring response to therapy. In this review, we assess new data in ACS with respect to troponins, BNPs, myeloperoxidase, fatty acid-binding protein, and monocyte chemoattractant protein-1. We also discuss novel biomarkers including growth deficient factor-15 and neopterin.

AB - Early diagnosis of acute coronary syndromes (ACS) allows for efficient risk stratification, appropriate targeted therapies, and faster patient disposition within crowded emergency departments. Although only troponin testing is recommended for routine use in the 2007 American College of Cardiology/American Heart Association guidelines for non-ST-elevation ACS, emerging data support selected use of other biomarkers, including B-type natriuretic peptides (BNPs) and C-reactive protein. There remains a need to identify additional biomarkers in ACS to enhance risk stratification and to help guide therapeutic decisions in this increasingly complex area of cardiovascular medicine. Cardiac biomarkers may help to diagnosis ACS before cardiomyocyte necrosis, to influence the decision for early invasive treatment, and to provide a means of monitoring response to therapy. In this review, we assess new data in ACS with respect to troponins, BNPs, myeloperoxidase, fatty acid-binding protein, and monocyte chemoattractant protein-1. We also discuss novel biomarkers including growth deficient factor-15 and neopterin.

UR - http://www.scopus.com/inward/record.url?scp=54449091304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449091304&partnerID=8YFLogxK

U2 - 10.1007/s11886-008-0051-z

DO - 10.1007/s11886-008-0051-z

M3 - Article

C2 - 18611367

AN - SCOPUS:54449091304

VL - 10

SP - 319

EP - 326

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 4

ER -